118 related articles for article (PubMed ID: 1420750)
1. Oral or intravenous erythromycin has no effect on human distal colonic motility.
Jameson JS; Rogers J; Misiewicz JJ; Raimundo AH; Henry MM
Aliment Pharmacol Ther; 1992 Oct; 6(5):589-95. PubMed ID: 1420750
[TBL] [Abstract][Full Text] [Related]
2. Effect of different doses of erythromycin on colonic motility in patients with slow transit constipation.
Bassotti G; Chiarioni G; Vantini I; Morelli A; Whitehead WE
Z Gastroenterol; 1998 Mar; 36(3):209-13. PubMed ID: 9577904
[TBL] [Abstract][Full Text] [Related]
3. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs.
Ozaki K; Sudo H; Muramatsu H; Yogo K; Kamei K; Koga H; Itoh Z; Omura S; Takanashi H
Inflammopharmacology; 2007 Feb; 15(1):36-42. PubMed ID: 17323194
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral erythromycin on colonic transit in patients with idiopathic constipation. A pilot study.
Sharma SS; Bhargava N; Mathur SC
Dig Dis Sci; 1995 Nov; 40(11):2446-9. PubMed ID: 7587829
[TBL] [Abstract][Full Text] [Related]
5. Motilides accelerate regional gastrointestinal transit in the dog.
Chiba T; Thomforde GM; Kost LJ; Allen RG; Phillips SF
Aliment Pharmacol Ther; 2000 Jul; 14(7):955-60. PubMed ID: 10886053
[TBL] [Abstract][Full Text] [Related]
6. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.
Talley NJ; Phillips SF; Haddad A; Miller LJ; Twomey C; Zinsmeister AR; MacCarty RL; Ciociola A
Dig Dis Sci; 1990 Apr; 35(4):477-80. PubMed ID: 2138532
[TBL] [Abstract][Full Text] [Related]
7. Effect of 4 x 250 mg erythromycin on human gastrointestinal transit.
Ueberschaer B; Ewe K; Alles U; Schmidtmann I
Z Gastroenterol; 1995 Jul; 33(6):340-4. PubMed ID: 7668024
[TBL] [Abstract][Full Text] [Related]
8. Erythromycin as a prokinetic agent in preterm infants.
Costalos C; Gounaris A; Varhalama E; Kokori F; Alexiou N; Kolovou E
J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):23-5. PubMed ID: 11753159
[TBL] [Abstract][Full Text] [Related]
9. The effect of erythromycin on motility of the duodenum, sphincter of Oddi, and gallbladder in the prairie dog.
Kaufman HS; Ahrendt SA; Pitt HA; Lillemoe KD
Surgery; 1993 Sep; 114(3):543-8. PubMed ID: 8367809
[TBL] [Abstract][Full Text] [Related]
10. Erythromycin shortens orocaecal transit time in diabetic male subjects: a double-blind placebo-controlled study.
Minocha A; Katragadda R; Rahal PS; Ries A
Aliment Pharmacol Ther; 1995 Oct; 9(5):529-33. PubMed ID: 8580273
[TBL] [Abstract][Full Text] [Related]
11. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
Houghton LA; Atkinson W; Whorwell PJ; Morris J; Murdoch RD; Cooper SM; Webber DM; Walls CM
Clin Ther; 2006 Apr; 28(4):569-81. PubMed ID: 16750468
[TBL] [Abstract][Full Text] [Related]
12. Oral erythromycin improves gastrointestinal motility and transit after subtotal but not total gastrectomy for cancer.
Altomare DF; Rubini D; Pilot MA; Farese S; Rubini G; Rinaldi M; Memeo V; D'Addabbo A
Br J Surg; 1997 Jul; 84(7):1017-21. PubMed ID: 9240156
[TBL] [Abstract][Full Text] [Related]
13. Assessment of large bowel motility by cine magnetic resonance imaging using two different prokinetic agents: a feasibility study.
Buhmann S; Kirchhoff C; Wielage C; Mussack T; Reiser MF; Lienemann A
Invest Radiol; 2005 Nov; 40(11):689-94. PubMed ID: 16230900
[TBL] [Abstract][Full Text] [Related]
14. Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study.
Dive A; Miesse C; Galanti L; Jamart J; Evrard P; Gonzalez M; Installé E
Crit Care Med; 1995 Aug; 23(8):1356-62. PubMed ID: 7634805
[TBL] [Abstract][Full Text] [Related]
15. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
16. Effects of erythromycin on gut transit in pseudo-obstruction due to hereditary coproporphyria.
Vassallo MJ; Camilleri M; Sullivan SN; Thomforde GM
J Clin Gastroenterol; 1992 Apr; 14(3):255-9. PubMed ID: 1564302
[TBL] [Abstract][Full Text] [Related]
17. [The potentials of erythromycin derivatives in the treatment of gastrointestinal motility disorders].
Peeters TL
Z Gesamte Inn Med; 1991 Aug; 46(10-11):349-54. PubMed ID: 1926941
[TBL] [Abstract][Full Text] [Related]
18. The effect of low-dose erythromycin on whole gastrointestinal transit time of preterm infants.
Costalos C; Gavrili V; Skouteri V; Gounaris A
Early Hum Dev; 2001 Dec; 65(2):91-6. PubMed ID: 11641030
[TBL] [Abstract][Full Text] [Related]
19. Motilin agonist erythromycin increases human lower esophageal sphincter pressure by stimulation of cholinergic nerves.
Chaussade S; Michopoulos S; Sogni P; Guerre J; Couturier D
Dig Dis Sci; 1994 Feb; 39(2):381-4. PubMed ID: 8313822
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravenous erythromycin on the colonic motility of children and young adults during colonic manometry.
Dranove J; Horn D; Reddy SN; Croffie J
J Pediatr Surg; 2010 Apr; 45(4):777-83. PubMed ID: 20385286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
